---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-092522"
form_type: "8-K"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2024-04-11T23:59:59+00:00"
generated_at: "2026-06-04T00:05:09.303233+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics reports positive Phase 1 data for ELVN-001 in CML; 44% MMR rate at 12 weeks

## Summary
- Cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable CML patients; 44% (4/9) in post-asciminib patients.
- No ≥ Grade 3 non-hematologic treatment-related adverse events; well tolerated with no dose reductions.
- ELVN-001 at ≥40mg QD shows superior target coverage vs 2nd-gen TKIs; PK supports once-daily dosing with no food effect.
- 89% of all enrolled patients remain on study; maximum tolerated dose not yet identified.
- Company hosting virtual event with key opinion leaders at 8:00 AM ET today to discuss data.

## SEC filing metadata
- accession: 0001193125-24-092522
- form_type: 8-K
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2024-04-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312524092522/0001193125-24-092522-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312524092522/d763719d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-092522
- JSON: https://secwatch.observer/filing/0001193125-24-092522.json
- Plain text: https://secwatch.observer/filing/0001193125-24-092522.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.